Endostatin

Specification

• Cat#: THP-0295
• Product Name: Endostatin
• Description: Endostatin is a naturally occurring, 20-kDa C-terminal fragment derived from type XVIII collagen. It is reported to serve as an anti-angiogenic agent, similar to angiostatin and thrombospondin. Endostatin is a broad-spectrum angiogenesis inhibitor and may interfere with the pro-angiogenic action of growth factors such as basic fibroblast growth factor (bFGF/FGF-2) and vascular endothelial growth factor (VEGF).
• Species: Human
• Molecular Weight: 20 kDa
• Purity: >99% by SDS-Page and HPLC analysis
• Cas No: 187888-07-9
• Endotoxin Level: <0.001 EU per 1 μg of the peptide by the LAL method

Pharmaceutical Information

• Pharmaceutical Application: Endostatin
• Applications: Investigated for use/treatment in cancer/tumors (unspecified), macular degeneration, and diabetic retinopathy.
• Examples of Clinical Use: Lung Cancer Non-Small Cell Cancer (NSCLC); Unspecified Adult Solid Tumor, Protocol Specific; Advanced Gastric Cancer; Advanced Well-differentiated Pancreatic Neuroendocrine Tumor
• Mechanism of action: Endostatin is an endogenous antitumor protein. Endostatin is a 20-kDa C-terminal fragment derived from type XVIII collagen which inhibits cell proliferation and migration, and induces endothelial cell apoptosis and cell cycle arrest. It is proposed that endostatin's effects are due to inhibition of vascular endothelial growth factor (VEGF) tyrosine phosphorylation of KDR/F1k-1 (VEGF receptor 2), the cell surface receptor for VEGF. VEGF is an important mediator of angiogensis. Endostatin additionally blocks activation of extracellular signal related kinases, or ERK, protein 38 mitogen activated protein kinase, or p38 MAPK (signal transduction pathways involving kinases that couple growth factors to cell surface receptors), as well as focal adhesion kinase (p125FAK). Studies are being done to determine if endostatin has possible impact on other pathways, and may also target E-selectin and block activity of metalloproteinases 2, 9 and 13. There is further research into a possible mechanistic link involving endostatin's angiogenic and zinc binding ability.